HC Wainwright Issues Positive Outlook for ARTV Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Investment analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for shares of Artiva Biotherapeutics in a research note issued on Wednesday, March 11th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.89) per share for the quarter, up from their previous forecast of ($0.96). The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.29) EPS, FY2026 earnings at ($4.18) EPS, FY2027 earnings at ($1.61) EPS, FY2028 earnings at ($1.11) EPS, FY2029 earnings at ($0.66) EPS and FY2030 earnings at ($0.36) EPS.

A number of other research analysts also recently weighed in on ARTV. Needham & Company LLC restated a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th. Finally, Jefferies Financial Group raised shares of Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Artiva Biotherapeutics Stock Down 8.4%

NASDAQ ARTV opened at $6.18 on Friday. The stock has a market capitalization of $152.77 million, a PE ratio of -1.81 and a beta of 2.16. Artiva Biotherapeutics has a 12-month low of $1.47 and a 12-month high of $7.75. The company has a 50 day moving average price of $4.77 and a two-hundred day moving average price of $3.97.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.03.

Institutional Trading of Artiva Biotherapeutics

Several large investors have recently modified their holdings of the company. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $41,000. Bank of America Corp DE grew its holdings in Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new position in Artiva Biotherapeutics in the 4th quarter worth approximately $91,000. Bridgeway Capital Management LLC bought a new position in Artiva Biotherapeutics in the 2nd quarter worth approximately $53,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Artiva Biotherapeutics during the second quarter worth approximately $58,000.

Artiva Biotherapeutics News Summary

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: HC Wainwright raised several multi‑period EPS forecasts, trimming projected losses across FY2026–FY2030 (e.g., FY2026 from ($4.26) to ($4.18); FY2027 from ($1.76) to ($1.61); FY2029 from ($0.74) to ($0.66); FY2030 from ($0.41) to ($0.36)). These revisions suggest modest improvement in the firm’s modeled outlook and can be supportive for the stock.
• Positive Sentiment: HC Wainwright also upgraded near‑term quarter forecasts for Q1–Q3 2026 (Q1: ($0.96) → ($0.89); Q2: ($1.05) → ($0.94); Q3: ($1.10) → ($1.06)), indicating better-than-previously-expected operating trajectory into 2026.
• Positive Sentiment: Needham & Company LLC initiated/issued a Buy rating for ARTV, which can attract demand from growth/biotech investors and provide short‑term upward pressure. Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Needham & Company LLC
• Neutral Sentiment: The company released its full‑year 2025 financial results and business highlights on March 11; investors will parse revenue, cash runway, and program updates in the filing/press release for longer‑term implications. Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
• Neutral Sentiment: Reported short‑interest data in mid‑March shows zero shares (and NaN changes), which appears to be a reporting anomaly and is not informative about true short pressure at this time.
• Negative Sentiment: HC Wainwright cut the Q4 2026 EPS view (worse) from ($1.16) to ($1.29), signaling a potentially weaker near‑term quarter that could weigh on sentiment if guidance or results mirror that pause.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.